FOLH1 and neoplasm: Against [68Ga]-PSMA-11, [68Ga]-MY6349 PET/CT demonstrated comparable lesion uptake, but better tumour-to-background contrast in primary and metastatic prostate cancer, allowing visualization of more metastatic lesions.